Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1392&sort=award_id
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=award_id", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1424&sort=award_id", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1393&sort=award_id", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1391&sort=award_id" }, "data": [ { "type": "Grant", "id": "9160", "attributes": { "award_id": "75N91019D00024-0-759102000003-46", "title": "Develop Pilot Program for Asymptomatic COVID-19 Testing for NCI-Frederick Staff", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-08-31", "end_date": "2021-08-30", "award_amount": 158000, "principal_investigator": { "id": 24928, "first_name": "LEONARD", "last_name": "FREEDMAN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1610, "ror": "", "name": "LEIDOS BIOMEDICAL RESEARCH, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1610, "ror": "", "name": "LEIDOS BIOMEDICAL RESEARCH, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "Test samples will be collected by the contractor from asymptomatic volunteers and will be open to all government and contractor staff. The samples will be transported the NIH Clinical Center for analysis. The scope of this effort includes all labor, equipment, logistics, materials and supplies, and management of test records. The collection, storage, and transportation of clinical samples will be in accordance with the NIH Clinical Center protocols.", "keywords": [ "COVID-19", "Clinical", "Collection", "Contractor", "Equipment", "Government", "Logistics", "Protocols documentation", "Records", "Sampling", "Testing", "Transportation", "United States National Institutes of Health", "clinical center", "cost", "programs", "volunteer" ], "approved": true } }, { "type": "Grant", "id": "7687", "attributes": { "award_id": "75N91019D00024-0-759102000008-1", "title": "ON BEHALF OF DCR FACILITATE THE CONDUCT OF AN OBSERVATIONAL STUDY TO CHARACTERIZE PATIENTS WITH COVID-19 INFECTION (10,000 SUBJECTS).", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-04-03", "end_date": "2021-04-02", "award_amount": 18109529, "principal_investigator": { "id": 23486, "first_name": "BETH", "last_name": "BASELER", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1610, "ror": "", "name": "LEIDOS BIOMEDICAL RESEARCH, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1610, "ror": "", "name": "LEIDOS BIOMEDICAL RESEARCH, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "This funding supports INSIGHT Protocol Number 011, International SARS-CoV-2 Infection Observational Study (ICOS). this is an international observational study of adult outpatients with SARS-CoV-2 Infection.", "keywords": [ "2019-nCoV", "Adult", "COVID-19", "Cessation of life", "Cohort Studies", "Consent", "Data Collection", "Disease Progression", "Funding", "Hospitalization", "Infection", "International", "Observational Study", "Outpatients", "Patients", "Procedures", "Protocols documentation", "Sample Size", "Site", "Testing", "follow-up", "primary endpoint" ], "approved": true } }, { "type": "Grant", "id": "7683", "attributes": { "award_id": "75N91019D00024-0-759102000009-1", "title": "ON BEHALF OF NIAID-DCR, FACILITATE THE CONDUCT OF TWO, RANDOMIZED TRIALS AS DETAILED BELOW IN I AND II:I.\tA RANDOMIZED BLINDED CONTROLLED TRIAL OF TH", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-04-03", "end_date": "2025-04-02", "award_amount": 67359812, "principal_investigator": { "id": 23486, "first_name": "BETH", "last_name": "BASELER", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1610, "ror": "", "name": "LEIDOS BIOMEDICAL RESEARCH, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1610, "ror": "", "name": "LEIDOS BIOMEDICAL RESEARCH, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "This funding supports INSIGHT Protocol Number: 013, Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC). It is an international multicenter, adaptive, randomized double-blind, placebo-controlled trial of the safety, tolerability, and efficacy of anti-coronavirus hyperimmune intravenous immunoglobulin for the treatment of adult hospitalized patients at the onset of clinical progression of COVID-19.", "keywords": [ "Adult", "Blinded", "COVID-19", "Categories", "Clinical", "Coagulation Process", "Consent", "Coronavirus", "Data", "Disease Progression", "Enrollment", "Ensure", "Functional disorder", "Funding", "Future", "Immunoglobulins", "Inpatients", "International", "Intravenous Immunoglobulins", "Life", "Medical", "National Institute of Allergy and Infectious Disease", "Organ", "Organ failure", "Outcome", "Participant", "Patients", "Pharmaceutical Preparations", "Placebos", "Protocols documentation", "Randomized", "Research Personnel", "Respiration Disorders", "Safety", "Sample Size", "Site", "Symptoms", "base", "double-blind placebo controlled trial", "individual patient", "mortality", "prevent", "primary endpoint", "randomized trial", "remdesivir", "standard of care", "study population" ], "approved": true } }, { "type": "Grant", "id": "7684", "attributes": { "award_id": "75N91019D00024-0-759102000010-1", "title": "The Adaptive COVID-19 Treatment Trial (ACTT)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-04-03", "end_date": "2025-04-02", "award_amount": 40199082, "principal_investigator": { "id": 23486, "first_name": "BETH", "last_name": "BASELER", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1610, "ror": "", "name": "LEIDOS BIOMEDICAL RESEARCH, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1610, "ror": "", "name": "LEIDOS BIOMEDICAL RESEARCH, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "To support randomized, controlled clinical trials to evaluate the safety and efficacy of investigational antiviral drugs against COVID-19.", "keywords": [ "Antiviral Agents", "COVID-19", "Investigation", "Randomized Controlled Clinical Trials", "Safety", "therapeutic evaluation", "treatment trial" ], "approved": true } }, { "type": "Grant", "id": "7685", "attributes": { "award_id": "75N91019D00024-0-759102000010-2", "title": "The Adaptive COVID-19 Treatment Trial (ACTT)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-04-03", "end_date": "2025-04-02", "award_amount": 18166213, "principal_investigator": { "id": 23486, "first_name": "BETH", "last_name": "BASELER", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1610, "ror": "", "name": "LEIDOS BIOMEDICAL RESEARCH, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1610, "ror": "", "name": "LEIDOS BIOMEDICAL RESEARCH, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "To support randomized, controlled clinical trials to evaluate the safety and efficacy of investigational antiviral drugs against COVID-19.", "keywords": [ "Antiviral Agents", "COVID-19", "Investigation", "Randomized Controlled Clinical Trials", "Safety", "therapeutic evaluation", "treatment trial" ], "approved": true } }, { "type": "Grant", "id": "7686", "attributes": { "award_id": "75N91019D00024-0-759102000011-1", "title": "NIAID BIG EFFECT TRIAL (BET) FOR COVID-19", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-05-01", "end_date": "2022-04-30", "award_amount": 25810387, "principal_investigator": { "id": 23486, "first_name": "BETH", "last_name": "BASELER", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1610, "ror": "", "name": "LEIDOS BIOMEDICAL RESEARCH, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1610, "ror": "", "name": "LEIDOS BIOMEDICAL RESEARCH, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "To support the Big Effect Trial (BET) to evaluate therapeutic agents against COVID-19.", "keywords": [ "COVID-19", "National Institute of Allergy and Infectious Disease", "Therapeutic Agents", "therapeutic evaluation" ], "approved": true } }, { "type": "Grant", "id": "9211", "attributes": { "award_id": "75N91019D00024-0-759102000025-1", "title": "DCR IS REQUESTING THE SERVICES OF LEIDOS BIOMEDICAL RESEARCH, INC. TO INITIATE MANAGEMENT, OVERSIGHT, EXECUTION, CLOSEOUT AND PUBLICATION OF FINDINGS", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-09-28", "end_date": "2025-09-27", "award_amount": 2539503, "principal_investigator": { "id": 23964, "first_name": "ETHAN", "last_name": "DMITROVSKY", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1610, "ror": "", "name": "LEIDOS BIOMEDICAL RESEARCH, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1610, "ror": "", "name": "LEIDOS BIOMEDICAL RESEARCH, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "The base of this funding will support an overall framework to allow NIAID to exercise up to 13 options for studies dealing with emerging and re-emerging Infectious Diseases that may include COVID-19.", "keywords": [ "Adult", "Biomedical Research", "COVID-19", "Characteristics", "Child", "Clinical", "Emerging Communicable Diseases", "Etiology", "Exercise", "Fever", "Funding", "National Institute of Allergy and Infectious Disease", "Observational Study", "Outcome", "Publications", "Services", "base", "pediatric patients", "prospective" ], "approved": true } }, { "type": "Grant", "id": "8072", "attributes": { "award_id": "75N91019D00024-0-759102100001-1", "title": "Frederick National Laboratory for Cancer Research (FNLCR) Center for SARS-CoV-2 Serological Sciences", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2021-02-11", "end_date": "2026-02-10", "award_amount": 85668587, "principal_investigator": { "id": 23964, "first_name": "ETHAN", "last_name": "DMITROVSKY", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1610, "ror": "", "name": "LEIDOS BIOMEDICAL RESEARCH, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1610, "ror": "", "name": "LEIDOS BIOMEDICAL RESEARCH, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "The purpose of the National Cancer Institute’s SARS-CoV-2 Serological Sciences Network (SeroNet) is to study the immune response to COVID-19 by developing and deploying serological assays of the highest specificity and sensitivity, expanding the national testing capacity for SARS-CoV-2 antibodies, and conducting research to develop understanding of immune responses to SARS-CoV-2. The FNLCR Center for SARS-CoV-2 Serological Sciences (the Center) is comprised of (1) Frederick National Laboratory (FNL) Serology Lab, (2) SARS-CoV-2 Serology Capacity Building Centers (CBCs), and (3) a Coordination Center that coordinates the activities of all SeroNet components. The Center’s priority for the FNL Serology Lab will be for the development and validation of serological antibody assays, including ELISAs, point of care lateral flow tests, and virus neutralization assays. The Center will also develop and disseminate the National SARS-CoV-2 serology standard that includes positive and negative controls along with proficiency panel samples. The Center will also implement laboratory based serology assays and increase assay throughput capabilities within the FNLCR Vaccine, Immunity and Cancer (VIC) Program and the CBCs for use in viral immunology studies to understand longitudinal responses to natural infection or vaccination and to determine correlates of protection against infection in sero-epidemiology studies with the NIH/NCI and outside community. The Center’s CBCs will build serological testing capacity by expanding testing to ~10K samples/week and conducting research in the natural history of infection or following vaccination to identify determinants of the immune response to SARS-CoV-2. The CBCs will also develop new assays as needed for deeper characterization of immune responses to the virus, vaccines, and correlates of protection. This may include development of assays for different functional aspects of the humoral responses, such as pseudovirus neutralization assays, determinants of antibody response and other relevant disease biomarkers. The data from these inter-collaborative studies, the U54 Serological Sciences Centers of Excellence, and U01 Research Projects in SARS-CoV-2 will be made available to the community through the Coordination Center within the Center.", "keywords": [ "2019-nCoV", "Antibodies", "Antibody Response", "Biological Assay", "Biological Markers", "COVID-19", "COVID-19 vaccination", "COVID-19 vaccine", "Communities", "Data", "Development", "Disease", "Enzyme-Linked Immunosorbent Assay", "Immune response", "Immunity", "Immunology", "Infection", "Laboratories", "Malignant Neoplasms", "NCI Center for Cancer Research", "National Cancer Institute", "Natural History", "Research", "Research Project Grants", "SARS-CoV-2 antibody", "Sampling", "Science", "Sensitivity and Specificity", "Serology", "Serology test", "Testing", "United States National Institutes of Health", "Vaccination", "Vaccine Research", "Vaccines", "Validation", "Viral", "Virus", "anticancer research", "assay development", "base", "epidemiology study", "lateral flow assay", "point of care", "programs", "response" ], "approved": true } }, { "type": "Grant", "id": "10217", "attributes": { "award_id": "75N91019D00024-0-759102200007-1", "title": "Phase 2 COVID-19 Vaccine Variant Clinical Trial", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2022-03-07", "end_date": "2024-03-06", "award_amount": 36854529, "principal_investigator": { "id": 26171, "first_name": "THERESA", "last_name": "ENGEL", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1610, "ror": "", "name": "LEIDOS BIOMEDICAL RESEARCH, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "To support a Phase 2 clinical trial evaluating various additional COVID-19 booster shots, the COVID-19 Variant Immunologic Landscape (COVAIL) clinical trial.", "keywords": [ "2019-nCoV", "COVID-19", "COVID-19 booster", "COVID-19 vaccine", "Clinical Trials", "Immunologics", "Phase", "Phase II Clinical Trials", "SARS-CoV-2 variant", "Vaccine Research", "Variant", "booster vaccine" ], "approved": true } }, { "type": "Grant", "id": "10621", "attributes": { "award_id": "75N91019D00024-0-759102200021-1", "title": "NIAID / CHILDRENS NATIONAL MEDICAL CENTER JOINT CLINICAL RESEARCH PROGRAM (JCRP) IMMUNOLOGIC AND INFECTIOUS DISEASES CLINICAL RESEARCH", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2022-09-02", "end_date": "2026-09-01", "award_amount": 3893764, "principal_investigator": { "id": 26665, "first_name": "KEVIN", "last_name": "NEWELL", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1610, "ror": "", "name": "LEIDOS BIOMEDICAL RESEARCH, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "This is a multisite prospective observational study to evaluate the clinical sequelae of symptomatic and asymptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the pediatric population (aged 0-21 years), including coronavirus disease 2019 (COVID-19) and multisystem inflammatory syndrome in children (MIS-C).", "keywords": [ "2019-nCoV", "COVID-19", "Child", "Childhood", "Clinical", "Clinical Research", "Communicable Diseases", "Evaluation", "Genetic", "Household", "Immune System Diseases", "Immune response", "Incidence", "Joints", "Medical", "Medical center", "Multisystem Inflammatory Syndrome in Children", "National Institute of Allergy and Infectious Disease", "Observational Study", "Outcome", "Population", "Prevalence", "Recovery", "Role", "SARS-CoV-2 infection", "Survivors", "aged", "biobank", "pediatric patients", "programs", "prospective" ], "approved": true } } ], "meta": { "pagination": { "page": 1392, "pages": 1424, "count": 14236 } } }